17 febbraio 2021 17:50
Fonte: Adnkronos
#salute-e-benessere
PROVIDENCE, R.I., Feb. 17, 2021 /PRNewswire/ EpiVax, Inc. ( EpiVax ) today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU, India, and United States (funded by the EU and India) with the aim of developing next-generation influenza vaccines with better responsiveness, lower costs, and better accessibility.
The INDIGO consortium, led by Dr. Remko van Leeuwen (INDIGO s Principal Investigator) of the Amsterdam Institute for Global Health and Development ( AIGHD ), plans to achieve this goal by exploring innovative influenza vaccine concepts. The group will aim to produce novel seasonal (A and B) and avian flu (H7N9 and H5N1) vaccines by combining three cutting-edge elements: novel recombinant HAs with increased immunogenicity, a potent adjuvant, and delivery via needle-free intradermal patches. The consortium will seek to valid